drugset / Trial / NCT01288404
Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium
RandomizedSingle-groupSingle-blindTreatment
Summary
Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.
Timeline
- Start
- 2008-01
- Primary completion
- 2010-09
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Other |
| Comparator | Bevacizumab | Monoclonal antibody | 2.5 mg | Other |
| Comparator | Bevacizumab | Monoclonal antibody | 3.75 mg | Other |
| Comparator | Fluorometholone | Other / unclassified | 0.1 % | Topical |